Background: Patients' negative expectations about medication can exacerbate side effect burden leading to low adherence and persistence. A novel intervention involves targeting mindsets about non-severe symptoms; reframing them as encouraging signs of medication working.
Purpose: This study aimed to assess whether a brief symptom-mindset intervention can improve symptom experience and adherence in patients starting methotrexate to treat an inflammatory rheumatic disease.
Methods: A randomized controlled trial was conducted with patients starting methotrexate. Participants were randomly assigned (1:1) to a mindset intervention or standard information control condition. Symptom mindset was assessed after 4 weeks to check intervention efficacy. The primary outcome was symptom experience after 4 weeks. Secondary outcomes were adherence and motivation to take methotrexate (4 weeks), as well as continuation and C-reactive protein (12 weeks).
Results: Forty-seven participants were randomly assigned to the intervention (n = 24) or control group (n = 23). All participants completed the study. After 4 weeks, compared to the control group, intervention participants endorsed more positive symptom mindsets, experienced less symptom burden (mean difference -2.70 [95% CI, -4.50, -0.90] P = .005), fewer general symptoms (3.53 [-6.99, .79] P = .045) and a similar number of methotrexate-specific symptoms (-0.79 [-2.29, 0.71] P = .295). The intervention group had better motivation and adherence to methotrexate at 4 weeks and better continuation, and C-reactive protein at 12 weeks than the control group. There was no difference in side effect attribution.
Conclusions: In patients starting methotrexate, a mindset intervention reframing the role of non-severe side effects is a promising approach for improving symptom experience and early stage medication persistence.
Keywords: arthritis; medication adherence; methotrexate; mindset; side effects (treatment).
The side effects patients experience when they start a new medication are a major barrier to adherence and treatment success in rheumatology. This study explored whether a brief (7.15-min) mindset intervention reframing common side effects as positive signals from the body that medication is working could improve patients’ early experiences of low-dose methotrexate. Participants were recruited after seeing their rheumatologist and being prescribed methotrexate to treat an inflammatory rheumatic condition. Participants were randomly allocated to the mindset intervention condition or to a standard information control condition, which included a 5.00-min video framing side effects as an unfortunate part of taking methotrexate. Compared with the standard information control group, the mindset intervention group had more positive mindsets about methotrexate symptoms, found them less burdensome, experienced fewer general symptoms and a similar number of symptoms specific to methotrexate. The mindset intervention group also had more motivation and better adherence to methotrexate after 4 weeks and were more likely to be taking methotrexate and have lower levels of C-reactive protein after 12 weeks. These findings support brief mindset-based interventions that give a truthful, positive explanation for the role of common side effects for medications like methotrexate to improve patients’ early treatment outcomes.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Society of Behavioral Medicine.